Age-specific false positives and the clinical pathway for a whole-blood DNA-methylation burden screen in older adults and carriers of clonal hematopoiesis: an open-data evaluation

Abstract Background. Whole-blood DNA-methylation readouts are proposed for early detection of myeloid neoplasms, but false positives in their intended users (older adults, many with clonal hematopoiesis of indeterminate potential [CHIP]) are unstudied. Objective. To measure age-specific false positives of a fixed 48-locus methylation burden call and model what a positive result should trigger. Methods. Pre-specified, public-data analysis. A positive call was ≥ 4 of 40 evaluable loci shifted ≥ 0.20 β from a reference built on 732 adults. It was applied to 917 samples from three cohorts without known myeloid disease (one pipeline from raw arrays), 540 repeat-sampling intervals and, as a sensitivity analysis, 2,639 processed samples. CHIP effects came from a meta-analysis (N = 8,196). A decision model compared single and repeat-draw strategies in CHIP carriers and unselected adults ≥ 60. Results. Positive calls rose with age: 0.3% (< 60 y), 1.9% (60–69), 2.5% (70–79) and 7.5% (≥ 80; 95% CI 4.3–12.7). Odds ratio per 10 years 2.22 (1.21–4.07). On repeat sampling, 6 of 17 positive draws (35%; 17–59) remained positive after a median 5.6 years. Published CHIP effects do not reach the call threshold at any locus. At an assumed sensitivity of 0.50 and age 70–79, positive predictive value was 1.8% in unselected adults and 9–29% in CHIP carriers (54% with a repeat draw); net benefit was near zero in unselected adults (at most 0.3 per 1,000) and positive in CHIP carriers (up to 9.8 per 1,000). Conclusions. False positives are infrequent below 80 years and rise thereafter. The plausible use is in known CHIP carriers: a confirmatory repeat draw, then hematologic work-up. Pre-diagnostic sensitivity remains unmeasured.

Authors

Publication Details

Journal
Research Square
Published
2026-11-12
DOI
https://doi.org/10.21203/rs.3.rs-10397076/v2
Primary Topic
Acute Myeloid Leukemia Research
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Age-specific false positives and the clinical pathway for a whole-blood DNA-methylation burden screen in older adults and carriers of clonal hematopoiesis: an open-data evaluation

Frederic Scheer
Research Square
Acute Myeloid Leukemia Research
preprint

Age-specific false positives and the clinical pathway for a whole-blood DNA-methylation burden screen in older adults and carriers of clonal hematopoiesis: an open-data evaluation

Frederic Scheer
preprint en

Abstract

Abstract Background. Whole-blood DNA-methylation readouts are proposed for early detection of myeloid neoplasms, but false positives in their intended users (older adults, many with clonal hematopoiesis of indeterminate potential [CHIP]) are unstudied. Objective. To measure age-specific false positives of a fixed 48-locus methylation burden call and model what a positive result should trigger. Methods. Pre-specified, public-data analysis. A positive call was ≥ 4 of 40 evaluable loci shifted ≥ 0.20 β from a reference built on 732 adults. It was applied to 917 samples from three cohorts without known myeloid disease (one pipeline from raw arrays), 540 repeat-sampling intervals and, as a sensitivity analysis, 2,639 processed samples. CHIP effects came from a meta-analysis (N = 8,196). A decision model compared single and repeat-draw strategies in CHIP carriers and unselected adults ≥ 60. Results. Positive calls rose with age: 0.3% (< 60 y), 1.9% (60–69), 2.5% (70–79) and 7.5% (≥ 80; 95% CI 4.3–12.7). Odds ratio per 10 years 2.22 (1.21–4.07). On repeat sampling, 6 of 17 positive draws (35%; 17–59) remained positive after a median 5.6 years. Published CHIP effects do not reach the call threshold at any locus. At an assumed sensitivity of 0.50 and age 70–79, positive predictive value was 1.8% in unselected adults and 9–29% in CHIP carriers (54% with a repeat draw); net benefit was near zero in unselected adults (at most 0.3 per 1,000) and positive in CHIP carriers (up to 9.8 per 1,000). Conclusions. False positives are infrequent below 80 years and rise thereafter. The plausible use is in known CHIP carriers: a confirmatory repeat draw, then hematologic work-up. Pre-diagnostic sensitivity remains unmeasured.

Research Square
Good health and well-being
Acute Myeloid Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon